Dickersin and Herxheimer
• How can the needs of patients and ethical considerations be satisfied and how may these considerations affect study quality?
• How can we ensure that the available evidence is collected systematically, completely, and kept up to date?
• Is the research community focusing too much on the quality of the evidence, while ignoring consumers', health care providers', and policy makers' need for more evidence?
Paul Stolley sets the scene by reminding us how shaky the foundations of clinical practice have been, even during our lifetime. His entertaining account makes a very serious point.
Even though randomized controlled trials are the most reliable source of evidence on the value of an intervention, not all are equally good. David Moher and his colleagues examine the thorny problems of assessing their quality and review the various approaches that have been tried. Whether the holy grail of a single numerical score to indicate the quality of a study will turn out to be a mirage remains to be seen.
Studies undertaken for commercial reasons have long been particularly suspected of bias, but such studies have only recently been systematically examined. Lisa Bero and Drummond Rennie describe the extent to which these suspicions are justified. Their thorough exploration of the many aspects of this issue provides many interesting examples.
The understandable impatience of sponsors and investigators to find quick answers has led to the widespread use of surrogate outcome measures instead of the longer-term outcomes that matter to patients. Peter G0tzsche and his colleagues warn us of the dangers of surrogates, giving examples where wrong conclusions long delayed the correct evaluation of important therapeutic interventions.
In the design of trials it is often difficult to strike the right balance between conflicting considerations, such as the desire to use random allocation to minimize bias and the desire to allow patients to choose the treatment that they prefer. Judith Lumley, working in perinatal medicine, and Hilda Bastian, a consumer advocate, consider the various conflicts that arise and cite numerous current examples.
A problem with published trial reports that has only recently been recognized stems from the fact that even a long and detailed paper can give only a summary of the data. Because space in paper journals is limited, much potentially important information about the trial inevitably remains unpublished and unknown. Lesley Stewart and Max Parmar discuss the many ways in which bias may enter into the conduct, analysis, and reporting of trials, and what reviewers can do to try to detect and correct such biases. Everyone who has to evaluate treatments will appreciate what they say. Systematic reviews are now accepted as an essential part of the evaluation of health care. The international Cochrane Collaboration is creating, maintaining, and disseminating systematic reviews of health care for all areas of medicine. The type of work that is involved in producing high-quality systematic reviews for the Cochrane Collaboration is described by Murray Enkin and Jini Hetherington, who pioneered it in the area of pregnancy and childbirth.
Finally, Chris Hyde, from his standpoint and experience as a public health physician developing policy from research results, explains that many obstacles have to be overcome for research findings to be translated into practice. The quality of evidence is only one of these hurdles.
Introduction
We hope that this special issue of the InternationalJournal of Technology Assessment in Health Care will be useful as a guide to aid research, reviews, teaching, and policy development in health care. It should help health professionals and consumers to recognize good studies, and authors and editors to eliminate reports that are uninformative and cloud our views about what "works."
